Loading…
← CockpitCompetitor Analysis › ERIS.NS Eris LifesciencesOpen in the cockpit ↗

Eris LifesciencesERIS.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major

Domestic-focused branded generics company selling diabetes, cardiac and dermatology drugs to Indian doctors and patients.

≈ A domestic-only Indian branded generics makerMomentum strong 68
Mkt cap
$1.98B
US dollars, full cap
Free float
32%
of shares outstanding
$/day
$1.82M
20-day average traded
Fwd P/E
27.9×
forward earnings
ROIC−WACC
-1.7 pp
WACC 12.0%
Hurdle
+5 pp
Req g minus delivered
Next earnings
65 days
22 Jan 2027
Close · INR₹1,337
1D-1.8%
1W+4.9%
1M+19.3%
3M-1.0%
6M+0.1%
YTD-11.2%
1Y-15.1%
ATR %3.2%
Beta0.56
52w lowhigh23.2% off high

What Eris Lifesciences does

Domestic-focused branded generics company selling diabetes, cardiac and dermatology drugs to Indian doctors and patients.

Sells prescription brands in India that doctors recommend and pharmacies stock, so revenue relies on field sales teams building prescribing habits in long-term therapy areas such as diabetes and heart disease, and on buying brands from other companies. Founder Amit Bakshi leads the company.

In one line: A domestic-only Indian branded generics maker.

Products and services

  • Diabetes/cardiac brands
  • Dermatology products
  • Nephrology/CNS drugs

Customers

  • Doctors/hospitals in India
  • Retail pharmacies

Where it sits in the supply chain

  • Formulation R&D
  • Manufacturing
  • Domestic branded generics distribution

What could go right

  • Domestic chronic disease drug growth
  • In-licensing/M&A of brands

What could go wrong

  • Fully domestic revenue concentration
  • Government price controls

Moat: narrow (brand, distribution). Strong doctor-relationship-driven brand building in chronic therapy areas within India.

Headquarters: Ahmedabad, India · Founded: 2007 · Employees: 3,076

Named competitors

Eris Lifesciences at a glance

Size Eris Lifesciences (ERIS.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $1.98B, the 378th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹1,337 on 18 Nov 2026.

Performance Over six months the shares gained 0.1%, against -5.5% for the median peer and +3.8% for the India market (cap-weighted) — 10th highest of 21 in its peer set.

Growth Revenue grew 11.1% over the last twelve months (peer median +10.7%); the operating margin is 26.3% (peer median 20.9%).

Valuation It trades at 27.9× forward earnings against a peer median of 18.1× (6th most expensive of 18).

Price implies For today's price to make sense, revenue must grow about 26% a year for seven years (Req g). Recent delivered growth is +21%, so the hurdle is +5 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 1.7 points below its cost of capital (12.0% WACC).

Next results Next results expected around 22 Jan 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026Peer median 97ERIS.NS 92
Six months, rebased to 100: Eris Lifesciences against the median of its 20 peers (local-currency closes).

Eris Lifesciences financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹33.3B₹31.3B₹28.9B₹20.1B₹16.9B
Revenue growth—+8%+44%+19%—
Gross profit₹15.9B₹14.3B₹13.0B₹10.1B₹8.54B
EBITDA₹11.6B₹11.3B₹10.3B₹7.01B₹5.47B
Net income₹7.08B₹6.20B₹3.52B₹3.92B₹3.82B
Free cash flown/a₹542M₹7.73B₹2.87B-₹5.69B
Capital expendituren/a₹2.97B₹1.55B₹1.29B₹8.41B
Total debt₹24.3B₹23.6B₹24.8B₹27.8B₹8.77B

Quarterly statements and history in the cockpit →

Eris Lifesciences competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%-10%0%+10%+20%9969009420BHVNONESOURCE300436HRMY60345660370760020145406002850512SHILPAMEDALIVUSH02PFIZER300009600211COHANCEERIS.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Eris Lifesciences is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%50×100×9969ONESOURCEHRMY6034566037076002014540SHILPAMEDH02PFIZER600211COHANCEERIS.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Eris Lifesciences is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%100%200%300%9969HRMY603456603707600201ERIS.NSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Eris Lifesciences is the large dot.

Eris Lifesciences competitors and peer comparison

Head to head with its named competitors (ERIS.NS vs MANKIND.NS vs TORNTPHARM.NS vs ALKEM.NS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Eris Lifesciences ERIS.NS$1.98B0%+11%26%27.9×26.3%
Mankind Pharma MANKIND.NS$11.6B+5%+13%21%44.4×28.6%
Torrent Pharmaceuticals TORNTPHARM.NS$18.8B+3%+42%22%70.2×37.6%
Alkem Laboratories ALKEM.NS$6.69B-5%+13%17%27.3×25.0%

How Eris Lifesciences compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Eris Lifesciences against its 20 peers (data as of 18 Nov 2026)
MeasureERIS.NSPeer medianRank in peer set
1-month return+19.3%+0.3%2nd highest of 21
6-month return+0.1%-5.5%10th highest of 21
Distance from 52-week high-23.2%-28.8%8th highest of 21
Revenue growth (TTM)+11.1%+10.7%10th highest of 20
Operating margin26.3%20.9%8th highest of 20
Forward P/E27.9×18.1×6th most expensive of 18
Growth the price implies (Req g, 7 yrs)26.3%1.7%most demanding of 14
Growth delivered (Del g)+20.9%+14.1%4th highest of 14
Hurdle (Req g minus delivered)+5.4 pp-12.8 pp4th most demanding of 14
ROIC minus cost of capital-1.7 pp+1.6 pp8th lowest of 20
EV / EBITDA17.8×16.6×6th cheapest of 11
Net debt / EBITDA1.9×0.7×3rd most indebted of 12

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Eris Lifesciences ERIS.NSIndia$1.98B0%+11%26%27.9×26.3%+20.9%
InnoCare Pharma 9969.HKHong Kong$2.01B-10%+146%35%32.2×-2.0%+341.1%
Hanall Biopharma 009420.KSSouth Korea$2.01B+12%+5%3%n/an/an/a
Biohaven BHVNUnited States$1.95B+46%n/an/an/an/an/a
OneSource Specialty Pharma ONESOURCE.NSIndia$1.95B-14%+11%6%44.6×n/an/a
Fujian Cosunter Pharmaceutical 300436.SZChina$2.02B-45%0%-47%n/an/an/a
Harmony Biosciences HRMYUnited States$1.94B+6%+20%22%8.6×-10.5%+40.3%
Zhejiang Jiuzhou Pharmaceutical 603456.SSChina$2.03B+19%-1%14%16.9×1.7%+15.7%
Nanjing King-friend Biochemical Pharmaceutical 603707.SSChina$2.03B-3%+9%14%25.9×5.1%+6.4%
Jinyu Bio-Technology 600201.SSChina$1.93B-21%+22%10%59.0×23.4%-2.5%
Tsumura & 4540.TJapan$1.93B+6%+13%18%10.4×n/an/a
Henan Lingrui Pharmaceutial 600285.SSChina$2.04B+9%+5%22%15.9×-4.7%+10.6%
Grand Pharmaceutical 0512.HKHong Kong$1.93B-25%+7%13%9.4×1.2%+14.1%
Shilpa Medicare SHILPAMED.NSIndia$1.91B+94%+37%21%54.3×n/an/a
Alivus Life Sciences ALIVUS.NSIndia$1.90B+36%+8%31%23.8×20.1%+6.2%
Haw Par H02.SISingapore$2.08B-25%-13%30%11.9×3.2%+15.7%
Pfizer PFIZER.NSIndia$1.88B-20%+12%34%21.9×11.2%+2.4%
Anhui Anke Biotechnology (Group) 300009.SZChina$1.88B-12%-9%30%18.1×8.0%+9.3%
Tibet Rhodiola Pharmaceutical 600211.SSChina$1.87B-8%+13%27%12.5×-1.2%+16.7%
PharmaResearch 214450.KSSouth Korea$2.10B-24%+29%37%15.4×-11.0%+37.6%
Cohance Lifesciences COHANCE.NSIndia$1.87B+7%+14%2%96.3×n/an/a

Questions

Who are Eris Lifesciences's main competitors?
Named competitors: Mankind Pharma (MANKIND.NS), Torrent Pharma (TORNTPHARM.NS), Alkem Laboratories (ALKEM.NS). The cockpit's measured peer set (industry) also includes InnoCare Pharma (9969.HK), Hanall Biopharma (009420.KS), Biohaven (BHVN), OneSource Specialty Pharma (ONESOURCE.NS), Fujian Cosunter Pharmaceutical (300436.SZ), Harmony Biosciences (HRMY).
Is Eris Lifesciences expensive compared with its peers?
On forward p/e it trades at 27.9× against a peer median of 18.1×, 6th most expensive of 18 in its peer set. For today's price to make sense, revenue must grow about 26% a year for seven years (Req g). Recent delivered growth is +21%, so the hurdle is +5 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Eris Lifesciences stock performed?
Over six months to 18 Nov 2026 the shares returned +0.1% against -5.5% for the median peer; over one year -15.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.